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Background: The natural history of ductal carcinoma in situ (DCIS) remains uncertain. The risk factors for
the development of invasive cancer in unresected DCIS are unclear.
Methods: Women diagnosed with DCIS on needle biopsy after 1997 who did not undergo surgical
resection for 1 year after diagnosis were identiﬁed by breast centres and the cancer registry and
outcomes were reviewed.
Results: Eighty-nine women with DCIS diagnosed 1998e2010 were identiﬁed. The median age at diag-
nosis was 75 (range 44e94) years with median follow-up (diagnosis to death, invasive disease or last
review) of 59 (12e180) months. Twenty-nine women (33%) developed invasive breast cancer after a
median interval of 45 (12e144) months. 14/29 (48%) with high grade, 10/31 (32%) with intermediate
grade and 3/17 (18%) with low grade DCIS developed invasive cancer after median intervals of 38, 60 and
51 months. The cumulative incidence of invasion was signiﬁcantly higher in high grade DCIS than other
grades (p ¼ .0016, log-rank test). Invasion was more frequent in lesions with calciﬁcation as the pre-
dominant feature (23/50 v. 5/25; p ¼ .042) and in younger women (p ¼ .0002). Endocrine therapy was
associated with a lower rate of invasive breast cancer (p ¼ .048).
Conclusions: High cytonuclear grade, mammographic microcalciﬁcation, young age and lack of endocrine
therapy were risk factors for DCIS progression to invasive cancer. Surgical excision of high grade DCIS
remains the treatment of choice. Given the uncertain long-term natural history of non-high grade DCIS,
the option of active surveillance of women with this condition should be offered within a clinical trial.
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Ductal carcinoma in situ (DCIS) is diagnosed predominantly
through mammographic screening programmes and now com-
prises 20% or more of new breast cancers [1]. Concern has been
expressed regarding possible overtreatment [2], given the excellent
long term survival of womenwith DCIS [3,4]. Some have suggested
that “nothing is better than something” [5] and proposed long-termvelopment of invasive cancer in unresected ductal carcinoma in situ,
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A.J. Maxwell et al. / European Journal of Surgical Oncology xxx (2018) 1e72surveillance for estrogen receptor (ER) positive DCIS [6,7]. Rando-
mised trials comparing the outcomes of active surveillance (AS)
with conventional surgery and adjuvant treatment have opened in
the UK (the LORIS trial) [8], the US (the COMET trial) [9] and Europe
(the LORD trial) [10]. Endocrine therapy in the AS arms is optional
in COMET, optional but not encouraged in LORIS and not allowed in
LORD.
While there is an historic literature describing the natural his-
tory of DCIS in small, predominantly pre-screening series of
symptomatic disease [11], there is also a growing understanding
that DCIS is a heterogeneous condition. It has been reported as a
common incidental ﬁnding at autopsy with a median 8.9% preva-
lence in a review of seven studies of women who died of unrelated
causes [12]. These series, conducted over 30 years ago, used vari-
able diagnostic criteria, compounded by the difﬁculty of diagnosing
DCIS in tissue that is likely to have been poorly preserved. The
current prevalence of undiagnosed DCIS therefore remains
uncertain.
Whatever the true prevalence, surgery, radiotherapy and
endocrine therapy remain the mainstays of guideline-concordant
care. However, some 2.0e2.3% of patients diagnosed with DCIS in
the USA choose AS for management of their disease [4,13]. Without
treatment, it has been estimated that only 20e30% of DCIS will
progress to invasive cancer [11,14].
Furthermore, it is not known whether long-term disease
outcome is adversely impacted by awaiting progression to invasive
disease.
Given this background, we sought to identify women in the
recent breast screening erawho had not received surgical resection
for histologically diagnosed DCIS and to consider risk factors and
long-term outcomes for such women as a comparator for active
surveillance trials.
Material and methods
The West Midlands Cancer Intelligence Unit (WMCIU, now
incorporated into the National Cancer Registration and Analysis
Service, part of Public Health England) and the Scottish Cancer
Registry identiﬁed 2505 possible eligible patients from cancer
registrations of women diagnosed in England and Scotland be-
tween 1 January 1996 and 31 December 2009
These women had a needle biopsy diagnosis of DCIS but no
record of subsequent surgery. Details were sent to Lead Clinicians in
each hospital following completion of a conﬁdentiality agreement.
In addition, National Health Service (NHS) Breast Units and NHS
Breast Screening Programme (NHSBSP) centres in the United
Kingdom were invited to submit details of known patients with
DCIS diagnosed from 1 January 2010 onwards who had not un-
dergone surgical excision for at least one year following conﬁrmed
histological diagnosis on needle biopsy. Additionally, some women
diagnosed between 2003 and 2012 were identiﬁed via the NHSBSP
prospective cohort study of screen-detected non-invasive neo-
plasias, the Sloane Project (www.sloaneproject.org.uk).
A comprehensive registration formwas completed for each case
by the submitting centre, including details of the imaging and
clinical ﬁndings, mode of biopsy, histopathology, reasons (where
known) for not performing surgery and relevant drug treatment
and/or radiotherapy. A follow-up form was completed for each
subsequent episode, which included one or more of clinical
assessment, mammogram and ultrasound (continuing drug treat-
ment was not formally recorded). A third form was completed for
any further needle biopsy or surgery. Forms were returned to the
WMCIU/Public Health England where the data were entered onto a
database. Missing data on tumour characteristics together with
date and cause of death were obtained from the National CancerPlease cite this article in press as: Maxwell AJ, et al., Risk factors for the de
European Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.eRegistration and Analysis Service. Data were exported to an Excel
spreadsheet for analysis. Registration opened in 2012 and closed in
December 2016.
Statistical methods
Univariate analysis only was performed due to the relatively
small size of the dataset. Comparisons of categorical data were
made using Fisher's Exact test. Continuous variables were assessed
by the Mann-Whitney U test. Cumulative incidence curves were
compared using Kaplan-Meier analysis and the log rank test.
Analysis was conducted using Stata version 14 (StataCorp LLC,
College Station, Texas, USA).
Results
Data from 89 eligible women identiﬁed from 31 breast units
were returned. In all cases the initial DCIS diagnoses were made
between 1998 and 2010 (no eligible cases diagnosed after 2010
were submitted despite speciﬁc requests for such cases). The me-
dian patient age at diagnosis was 75 years (range 44e94 years). The
DCIS was screen-detected in 39 women (44%) with a median age of
65 years; the remaining 50 were diagnosed through other routes
(symptomatic clinics and incidental ﬁndings) and had amedian age
of 82 years. The median duration of follow-up (diagnosis to death,
invasive disease or last review) was 59 months (range 12e180
months).
The symptoms of the 50womenwhowere diagnosed other than
through screening are poorly documented. Three each presented
with a lump, a nipple discharge and nipple changes. Clinical ex-
amination was recorded as normal in 7, benign in 3, indeterminate
in 9, suspicious in 8 and malignant in 8; clinical ﬁndings were not
recorded in 15. It is likely that a number of DCIS lesions were
incidentally detected on mammography performed for investiga-
tion of unrelated symptoms.
Thirty-ﬁve women (39%) were recorded as being unﬁt for sur-
gery (without details of the comorbidities), 37 (42%) declined sur-
gery, four (4%) were both unﬁt and declined surgery, other
(unspeciﬁed) reasons were stated for eight (9%) and the reasons
were unknown for ﬁve (6%) patients.
Mammographic features
The predominant mammographic features were known for 75
of the 89 women. Fifty (67%) were microcalciﬁcation, granular
microcalciﬁcation being the most common. Nine of the 25 women
with other predominant features (mass or deformity) had micro-
calciﬁcation as a secondary feature. The median mammographic
lesion size for women in whom both size and grade were known
was 34 mm (range 8e88) for high grade DCIS (n ¼ 23), 32 mm
(5e126) for intermediate grade DCIS (n¼ 23) and 15mm (4e64) for
low grade DCIS (n ¼ 11).
Needle biopsy
In 63women, the initial DCIS diagnosis wasmadewith 14-gauge
(G) core needle biopsy (CNB). Only tenwomenwere known to have
been diagnosed with vacuum-assisted biopsy (VAB) (one each of
14G and 11G, ﬁve 10G and unknown gauge in three). In sixteen
women, the biopsy technique was classed as either ‘other’ or un-
known but were not open biopsies (12 were image-guided and one
freehand; the remaining three were inwomen unﬁt for surgery). Of
the 72 womenwhere themode of guidancewas known, 37 biopsies
were performed under stereotaxis, 28 ultrasound and sevenvelopment of invasive cancer in unresected ductal carcinoma in situ,
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aspiration cytology.
Cytonuclear grade of DCIS and presence of microinvasion
The grade of the DCIS at needle biopsy was known for 77 of the
89 women. Twenty-nine were high, 31 intermediate and 17 low
grade. Microinvasionwas only recorded as deﬁnitely present in one
woman (grade unknown) and possibly present in four (one low
grade, one intermediate grade, one high grade, one grade not
known). Microinvasion was speciﬁcally stated to be absent on
needle biopsy in 59 and not stated (presumed absent) in 25.
Histological necrosis
The presence or absence of histological necrosis in association
with the DCIS was recorded in 53 women. Of the 50 in whom both
necrosis status and the primary mammographic feature were
known, 9/31withmicrocalciﬁcation and 4/19with another primary
radiological feature had necrosis (p ¼ .742, Fisher exact test).
Estrogen receptor (ER) status
ER status was positive in 43 of the 48 women in whom ER was
recorded (positivity was regarded as an Allred score 3/8 where
the score was stated, otherwise as deﬁned by the submitting
centre).
Non-surgical treatment
Forty-four women were treated with endocrine therapy (ET) -
26 with an aromatase inhibitor, 17 with tamoxifen and one with
each type sequentially. One woman treated with an aromatase in-
hibitor also received external beam radiotherapy. Thirty women
treated with ET were recorded as having known ER positive DCIS.
Thirty-ﬁve women received no ET; eight were known to have ER
positive disease. Non-surgical treatment information was not
available for 10 women.
Development of invasive cancer
Twenty-nine women (33%) had invasive breast cancer diag-
nosed histologically after a median interval of 45 months (range
12e144 months) following the initial DCIS diagnosis. A further ﬁve
women who died had invasive breast cancer recorded as their
primary cause of death on death certiﬁcation but no histological
conﬁrmation of this was recorded on the cancer registry; these ﬁve
were not included amongst those who developed invasive cancer
for the purposes of this analysis (see discussion). The 29 women
who developed proven invasive cancer were signiﬁcantly youngerTable 1
Predominant radiological feature and cytonuclear grade of DCIS at core needle biopsy (d
Predominant radiological feature Low grade Intermediate grade
Microcalciﬁcation - casting 0/1 3/8
Microcalciﬁcation - granular 1/2 4/9
Microcalciﬁcation - punctate 2/3 0/0
Microcalciﬁcation - pattern not known 0/0 1/6
Mass e ill-deﬁned 0/1 1/1
Mass e well-deﬁned 0/2 0/1
Spiculate mass 0/2 0/0
Stromal deformity 0/0 0/0
None of the above 0/3 0/1
Not known 0/3 1/5
Total 3/17 10/31
Please cite this article in press as: Maxwell AJ, et al., Risk factors for the de
European Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.ethan the 60 who did not (median ages 67 years versus 78 years
respectively; p ¼ .0002, Mann-Whitney U Test). Younger women
had a similar median length of follow-up to older women (age 70
years v. age>70 years: 60 months v. 58 months; p ¼ .45; Mann-
Whitney U test), although there was a non-signiﬁcantly higher
proportion of younger womenwith high grade disease (39% v. 27%;
p ¼ .26, Fisher exact test).
One invasive cancer was recorded as having developed in the
same breast but a different quadrant to the known high grade DCIS;
this has been included as a case of DCIS progression for consistency
with other published studies. As far as is known, the remaining 28
invasive cancers developed at the site of the DCIS.
Comparison of DCIS grade on the initial biopsy and the pre-
dominant mammographic feature for those with and without
progression to invasive cancer is shown in Table 1. After median
intervals of 38, 60 and 51 months respectively, 14/29 (48%) women
with high grade DCIS, 10/31 (32%) with intermediate grade and 3/
17 (18%) with low grade DCIS developed invasive cancer; grade
was not known in 12. The cumulative incidence of invasive disease
was signiﬁcantly higher in women with high grade DCIS than in
those with other grades (p ¼ .0016, log-rank test) e Fig. 1. None of
the ﬁve women with microinvasion on the initial biopsy devel-
oped invasive breast cancer. All six of the grade 3 invasive cancers
occurred in women with a prior diagnosis of high grade DCIS
(Table 2).
Twenty-three of the 50 (46%) womenwith microcalciﬁcation as
the predominant radiological feature developed invasion compared
to only ﬁve of the 25 (20%) with another known predominant
radiological feature (p ¼ .042, Fisher exact test).
Of the 53 women with known histological necrosis status, 7/14
(50%) with necrosis and 13/39 (33%) without necrosis developed
invasive cancer (p ¼ .341, Fisher exact test).
For those with known DCIS grade and mammographic size, no
correlation between lesion size and the subsequent development of
invasion was demonstrated (p ¼ .109e.921; Mann-Whitney U test;
data not shown).
Nine of 44 women (20%) who received endocrine therapy
developed invasive cancer compared to 15 of 35 (43%) who did not
(p ¼ .048, Fisher exact test).
Of the 25 knownwomenwho did not have microcalciﬁcation as
the predominant feature, four of the 10 (40%) with secondary
microcalciﬁcation developed invasive cancer compared to one of
the 15 (7%) without microcalciﬁcation (p ¼ .12, Fisher exact test).
Surgery
Eighteen women ultimately underwent breast surgery, seven-
teen for invasive cancer: Thirteen had mastectomy and four wide
local excision. One woman had a wide local excision for DCIS 12
months after initial diagnosis.enominators) and numbers that developed invasive cancer (numerators).
High grade Grade not known Total
3/6 1/2 7/17 Microcalciﬁcation 23/50
5/8 0/0 10/19
1/2 0/0 3/5
2/2 0/1 3/9
0/1 1/1 2/4 Mass 5/18
2/4 0/3 2/10
1/1 0/1 1/4
0/2 0/0 0/2
0/0 0/1 0/5
0/3 0/3 1/14
14/29 2/12 29/89
velopment of invasive cancer in unresected ductal carcinoma in situ,
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Fig. 1. Cumulative incidence of invasive cancer by DCIS grade. Kaplan-Meier chart showing the cumulative incidence of invasive cancer from time of DCIS diagnosis by cyto-
nuclear grade of DCIS.
Table 2
Invasive carcinoma type and histological grade and the cytonuclear grade of the original DCIS, where known.
Original DCIS grade IDC grade 1 IDC grade 2 IDC grade 3 Other invasive cancer Not known Total
High 0 2 6 1 invasive lobular carcinoma grade 2 5 14
Intermediate 2 3 0 1 mixed carcinoma 4 10
Low 1 1 0 0 1 3
Not known 0 0 0 1 invasive lobular carcinoma grade 2; 1 invasive papillary carcinoma 0 2
Total 3 6 6 4 10 29
IDCeInvasive ductal carcinoma.
A.J. Maxwell et al. / European Journal of Surgical Oncology xxx (2018) 1e74Deaths
Forty-eight women died. Eleven of these had biopsy-proven
invasive cancer, of whom seven had a primary certiﬁed cause of
death of breast cancer.
For women that developed invasive cancer the median interval
from diagnosis to death was 62 months for all-cause deaths and 62
months for deaths from breast cancer. For those that did not
develop invasive cancer the median interval was 57 months
(p ¼ .28, Mann-Whitney U Test).
Among the 29 women with invasive cancer, there was no sig-
niﬁcant difference between the age at diagnosis of DCIS for those
who died compared with the women still alive at census (median
ages 68 years v. 66 years respectively; p ¼ .62, Mann-Whitney U
Test). However, of the womenwho did not develop invasive cancer,
those who died were signiﬁcantly older at diagnosis than those
who remained alive (median ages 83 years v. 69 years; p ¼ .0001,
Mann-Whitney U Test).
Discussion
This retrospective longitudinal cohort study of women diag-
nosed with DCIS on core needle biopsy who did not undergo sur-
gical excision for at least one year reviewed 89 eligible women.
Progression to invasive breast cancer was more frequent in a shortPlease cite this article in press as: Maxwell AJ, et al., Risk factors for the de
European Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.etime frame for those with initial DCIS of high cytonuclear grade.
The Kaplan-Meier analysis suggests that approximately 50% of
women with high grade DCIS will develop invasive cancer within
ﬁve years but fewer than 25% of those with lower grade DCIS will
develop invasion in the same time frame. In particular, low grade
DCIS appears to progress slowly to invasive cancer. For approxi-
mately one in seven of thewomenwho died, the cause of death was
attributed to breast cancer, with a median survival in these women
of over ﬁve years from DCIS diagnosis.
The tendency for high grade DCIS to be associated with grade
3 invasive cancer and the signiﬁcantly higher cumulative inci-
dence of invasion suggest that the biological behaviour is
reﬂected in the histopathological appearances of the DCIS. This
effect of grade is similar to that seen for DCIS recurrence
following surgical resection [15]. Our ﬁndings emphasise the
importance of early detection and treatment of women with high
grade DCIS in order to prevent the development of high grade
invasive cancer.
Evenwith the confounding factor of a slightly higher proportion
of high grade disease in the younger (70 years) women, the rate of
progression to invasion does appear to be higher in younger
women. This is in keeping with the known higher local recurrence
rate in youngerwomen following surgical resection of DCIS [1,16,17]
and with the higher proportion of invasive recurrences seen in
these women [18].velopment of invasive cancer in unresected ductal carcinoma in situ,
jso.2017.12.007
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development of invasive disease has not been previously reported,
although microcalciﬁcation has been shown to be associated with a
higher risk of non-invasive recurrence [19]. In addition, there have
been some suggestions that invasive cancers with micro-
calciﬁcation have a worse prognosis than non-calciﬁed lesions
[20e22], although this is not a consistent ﬁnding [23] and may be
due to confounding factors [24]. Our ﬁndings are rather at variance
with those of other studies which have shown a higher upstaging
rate at surgery of DCIS with an associated mammographic mass
[25,26], and the small number of women with masses in this study
precludes further analysis of possible confounding factors.
The effect of endocrine therapy in reducing progression of DCIS
to invasive cancer noted here is consistent with the ﬁndings of trials
of adjuvant endocrine therapy following surgery for DCIS. The UK/
ANZ DCIS trial [27] and the NSABP B-24 study [28] demonstrated a
signiﬁcant reduction in the frequency of DCIS recurrence with
tamoxifen, although the UK/ANZ study did not show a signiﬁcant
reduction in invasive recurrence. Anastrozole has subsequently
been demonstrated to be at least as effective as tamoxifen in this
setting [29,30].
The contribution of DCIS detection at screening to reduction of
breast cancer mortality has long been debated. A review of prior
mammograms of women with incident screen-detected cancers
suggested that undiagnosed calciﬁed DCIS progresses to invasive
cancer within the three-year period between screens in a signiﬁ-
cant number of women [31], but only recently have data been
published that demonstrate that high DCIS detection rates at
screening are associated with a reduction in the incidence of in-
terval cancers [32].
Sagara et al. [4] reported outcomes of 57,222 women with DCIS
from the SEER (Surveillance, Epidemiology and End Results) data-
base, of whom 1169 (2%) had not undergone surgical resection.
Although the development of invasive disease was not speciﬁcally
examined, for womenwith high and intermediate grade DCIS there
was a signiﬁcant difference in 10-year breast cancer speciﬁc sur-
vival between thosewho underwent surgery and thosewho did not
(98.4% v. 90.5%, p < .001, for high grade; 98.6% v. 94.6%, p < .001, for
intermediate grade disease, respectively). Surgery was not, how-
ever, associatedwith a survival difference inwomenwith lowgrade
DCIS (98.6% v. 98.8%; P ¼ .95). The median follow-up, however, was
only six years, and further study is required to determine whether
this effect persists in the longer term (cf. the discussion below
about long term recurrence rates after surgery). A series following
14 women with ER positive DCIS who underwent endocrine ther-
apy as an alternative to immediate surgery [6] reported that eight
subsequently had surgery after a median follow-up of 28 months;
ﬁve had with stage I invasive ductal cancers. Although there were
only 17 womenwith lowgrade DCIS in the present study, eight died
of non-breast cancer related causes and the ﬁndings suggest that
low grade DCIS is a relatively indolent disease. Of the three women
who did develop invasion after intervals of 46, 51 and 137 months,
one of the invasive cancers was of histological grade 1, one grade 2
and the other was of unknown grade. These ﬁndings, together with
the demonstrated lack of survival beneﬁt from surgery [4], also
support ongoing studies of active surveillance as an alternative to
surgery in low risk DCIS [8e10].
To our knowledge, this is the largest study reporting the pro-
gression of histologically conﬁrmed unresected DCIS to invasive
breast cancer. Diagnostic and treatment data were obtained from
clinicians managing the women, supplemented by cancer registry
data, and consequently data completeness is relatively high.
Although variability in the application of diagnostic and grading
criteria to DCIS by histopathologists is well recognised [33], the
mandatory participation in a national quality assurancePlease cite this article in press as: Maxwell AJ, et al., Risk factors for the de
European Journal of Surgical Oncology (2018), https://doi.org/10.1016/j.eprogramme by all UK pathologists working in breast screening [34]
provides some reassurance.
This study has limitations. Despite the large number of women
with a DCIS diagnosis but no record of surgery on the cancer reg-
istries (2505 (5%) potentially eligible out of a total of 49,567 DCIS
registrations in the period 1996e2009), only a relatively small
number of patients (0.2%) had data submitted by the treating
centres, with potential for selection bias. The proportion of women
diagnosed with DCIS in the UK who do not undergo surgery is,
therefore, unknown, but appears similar to the 2.0e2.3% reported
in the USA [4,13]. Because of the nature of the study population
(with regard to patient age and associated co-morbidities), many of
the women died of competing causes during the course of the
study, substantially limiting the duration of follow-up. Further-
more, there were relatively few younger women with screen-
detected DCIS. Given that DCIS is most commonly diagnosed
through screening [35,36], the disproportionate number of women
in this study with DCIS diagnosed through other routes (either
symptomatic or incidentally detected on mammography per-
formed for investigation of unrelated symptoms) is probably
because screening mammography in the UK is targeted at women
aged 70 years of age or younger who are more likely to be suitable
for, and to be willing to undergo, primary surgical resection of DCIS
than older women who were diagnosed outside the screening
service.
Although endocrine treatment was recorded on the initial
assessment form it was not recorded on the subsequent forms and
it is possible that some women stopped treatment, or conversely
that others commenced treatment.
Five women died with a primary certiﬁed cause of death of
breast cancer but no corresponding cancer registration of invasive
breast cancer. These have not been included as having developed
invasive disease in the analysis. This is because there is known to be
a high discrepancy rate in death certiﬁcation, with up to a third of
deaths being incorrectly certiﬁed [37], whereas the UK cancer
registries (now uniﬁed as the National Cancer Registration and
Analysis Service) have an ascertainment rate of around 98% [38]. It
is, however, possible that the number of women who developed
invasive cancer has been slightly understated.
Although the rate of development of invasive cancer in women
with low grade DCIS appears to be much lower than that in women
with high grade DCIS in the short term (the median follow-up was
just under 5 years), it is not possible to determine the longer-term
behaviour of low grade DCIS from this study. Solin et al., [39] in a
study of 268 women with DCIS treated by wide local excision and
radiotherapy, demonstrated that the local recurrence rate of high
grade DCIS with necrosis was four times that of the other lesions
at 5 years (12% v 3%) but that continued recurrences in the less
aggressive group brought the rates much closer together by 10
years (18% v. 15%). A similar but less marked effect was seen in
the Early Breast Cancer Trialists' Collaborative Group overview of
randomised radiotherapy trials in DCIS [40]. The proportion of
women developing invasive cancer can, therefore, be expected to
be higher in a population with a longer life expectancy, especially
as the rate of progression appears to be higher in younger
women.
The majority of women in the study underwent conventional
core needle biopsy rather than vacuum-assisted biopsy for diag-
nosis. CNB is known to underestimate the coexistence of invasive
disease in DCIS in approximately 20% of cases [25,41,42].
Nonetheless, the study still allows a ‘real world’ approach to the
outcome of DCIS diagnosed predominantly at CNB to be deter-
mined. Finally, due to the relatively small number of subjects,
multivariable analysis was not possible, thus confounding factors
cannot be excluded.velopment of invasive cancer in unresected ductal carcinoma in situ,
jso.2017.12.007
A.J. Maxwell et al. / European Journal of Surgical Oncology xxx (2018) 1e76Conclusions
High cytonuclear grade of DCIS, mammographic micro-
calciﬁcation, young age and lack of endocrine therapy were sig-
niﬁcant risk factors for progression to invasive breast cancer after a
median interval of 45 months in this group of women diagnosed
with DCIS on needle biopsy but who did not undergo surgical
resection for at least one year. These ﬁndings suggest that complete
surgical excision of high grade DCIS should continue, as per current
standard of care protocols. The natural history of low grade DCIS,
however, remains uncertain. Whilst there are concerns about
possible overtreatment of women with this condition, established
management practice should not be changed in the absence of ﬁrm
evidence, and the option of active surveillance for women with
non-high grade DCIS should be offered within the context of a
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